Novartis (NVS) Competitors

$97.49
+0.36 (+0.37%)
(As of 05/1/2024 ET)

NVS vs. ABT, AZN, PFE, SNY, ABBV, VRTX, REGN, BMY, GSK, and ZTS

Should you be buying Novartis stock or one of its competitors? The main competitors of Novartis include Abbott Laboratories (ABT), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY), AbbVie (ABBV), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Bristol-Myers Squibb (BMY), GSK (GSK), and Zoetis (ZTS). These companies are all part of the "pharmaceutical preparations" industry.

Novartis vs.

Novartis (NYSE:NVS) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Abbott Laboratories received 391 more outperform votes than Novartis when rated by MarketBeat users. Likewise, 69.60% of users gave Abbott Laboratories an outperform vote while only 61.42% of users gave Novartis an outperform vote.

CompanyUnderperformOutperform
NovartisOutperform Votes
527
61.42%
Underperform Votes
331
38.58%
Abbott LaboratoriesOutperform Votes
918
69.60%
Underperform Votes
401
30.40%

Novartis currently has a consensus target price of $115.00, suggesting a potential upside of 18.02%. Abbott Laboratories has a consensus target price of $121.50, suggesting a potential upside of 13.90%. Given Novartis' higher possible upside, research analysts clearly believe Novartis is more favorable than Abbott Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novartis
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Abbott Laboratories
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.67

13.1% of Novartis shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Novartis has higher revenue and earnings than Abbott Laboratories. Novartis is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$45.44B4.37$14.85B$7.4113.12
Abbott Laboratories$40.11B4.61$5.72B$3.2133.19

Novartis has a net margin of 31.33% compared to Abbott Laboratories' net margin of 13.96%. Novartis' return on equity of 32.15% beat Abbott Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Novartis31.33% 32.15% 13.59%
Abbott Laboratories 13.96%20.32%10.59%

In the previous week, Abbott Laboratories had 5 more articles in the media than Novartis. MarketBeat recorded 17 mentions for Abbott Laboratories and 12 mentions for Novartis. Abbott Laboratories' average media sentiment score of 0.73 beat Novartis' score of 0.32 indicating that Abbott Laboratories is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novartis
5 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Abbott Laboratories
8 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Novartis pays an annual dividend of $2.43 per share and has a dividend yield of 2.5%. Abbott Laboratories pays an annual dividend of $2.20 per share and has a dividend yield of 2.1%. Novartis pays out 32.8% of its earnings in the form of a dividend. Abbott Laboratories pays out 68.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novartis has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

Summary

Abbott Laboratories beats Novartis on 11 of the 20 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVS vs. The Competition

MetricNovartisPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$198.74B$6.62B$4.88B$17.42B
Dividend Yield2.50%2.90%2.81%3.53%
P/E Ratio13.1211.76193.5522.58
Price / Sales4.37293.922,465.5110.26
Price / Cash8.7430.5846.4917.73
Price / Book5.005.884.734.86
Net Income$14.85B$140.75M$102.52M$964.11M
7 Day Performance-1.14%1.80%1.33%-0.79%
1 Month Performance1.43%-9.87%-6.01%-4.42%
1 Year Performance-5.18%-2.15%4.45%94.09%

Novartis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABT
Abbott Laboratories
4.9929 of 5 stars
$105.94
-1.2%
$121.50
+14.7%
-4.1%$183.82B$40.11B33.00114,000
AZN
AstraZeneca
1.6389 of 5 stars
$75.88
+0.5%
$81.00
+6.7%
+3.6%$235.26B$45.81B37.2089,900Short Interest ↑
Analyst Revision
PFE
Pfizer
4.9794 of 5 stars
$25.61
-0.1%
$36.33
+41.9%
-34.1%$145.02B$58.50B71.1488,000Dividend Announcement
Gap Up
SNY
Sanofi
2.7029 of 5 stars
$49.23
+0.3%
$55.00
+11.7%
-8.2%$124.53B$46.61B24.7486,088Short Interest ↓
Analyst Revision
ABBV
AbbVie
4.8183 of 5 stars
$162.69
+0.7%
$174.31
+7.1%
+7.7%$288.07B$54.32B48.2850,000Earnings Report
Analyst Report
Analyst Revision
VRTX
Vertex Pharmaceuticals
4.3294 of 5 stars
$392.81
-0.9%
$429.45
+9.3%
+15.3%$101.53B$9.87B28.285,400Upcoming Earnings
REGN
Regeneron Pharmaceuticals
3.954 of 5 stars
$890.66
-0.2%
$977.77
+9.8%
+11.1%$97.76B$13.12B25.6313,450Upcoming Earnings
Analyst Downgrade
Insider Selling
BMY
Bristol-Myers Squibb
4.9405 of 5 stars
$43.96
-1.5%
$60.00
+36.5%
-34.2%$89.11B$45.01B-14.1834,100Earnings Report
Options Volume
Analyst Revision
GSK
GSK
2.6742 of 5 stars
$41.43
-0.4%
N/A+15.0%$85.86B$37.71B13.7670,200News Coverage
Gap Up
ZTS
Zoetis
4.8953 of 5 stars
$159.17
-0.3%
$218.00
+37.0%
-9.4%$72.80B$8.54B31.3914,100Upcoming Earnings
Analyst Report
Analyst Revision

Related Companies and Tools

This page (NYSE:NVS) was last updated on 5/1/2024 by MarketBeat.com Staff

From Our Partners